Literature DB >> 15095955

Expression of estrogen receptors alpha and beta in human osteoblasts: identification of exon-2 deletion variant of estrogen receptor beta in postmenopausal women.

Fang-Ping Chen1, Todd Hsu, Chin-Hwa Hu, Wen-Der Wang, Kun-Chuang Wang, Li-Fen Teng.   

Abstract

BACKGROUND: Postmenopausal osteoporosis is associated with estrogen deficiency. Estrogens have effects on bone metabolism, which are mediated by estrogen receptors (ERs). If estrogen responsiveness is related to the ER expression level, ER expression in postmenopausal women should be different from previous studies using osteoblast lineage. We investigated the expression of variant isoforms of ER messenger ribonucleic acid (mRNA) in osteoblasts (OB) from postmenopausal women and a human osteosarcoma cell line, MG 63.
METHODS: Osteoblast cultures were prepared from the upper femur of postmenopausal patients or MG 63. For OB cultures at 5, 10, 15, 20, and 25 days, the expressions of ERalpha and beta mRNA were examined using reverse transcriptase-polymerase chain reaction.
RESULTS: In MG 63, ERbeta mRNA was constantly and highly expressed during the 25-day culture, whereas ERalpha mRNA was barely detected. In the primary OB cells, both ERalpha and beta mRNA were transcribed during the 25-day culture, but expression of ERalpha mRNA was much stronger than that of ERbeta mRNA. A splice variant form of ERbeta mRNA that was missing the entire exon 2 (ERbeta delta 2) was detected and heterogeneously expressed in OB cultures from 16 postmenopausal women.
CONCLUSION: Differential expressions of these ER isoforms suggest that they may have different functions or that they interact with each other during bone metabolism. The different ratio of ERbeta to ERbeta delta 2 mRNA or ERalpha to ERbeta mRNA expressions in osteoblast cultures may be related to different bone conditions. Whether the presence of ERbeta delta 2 in postmenopausal women influences the biological properties of bone needs to be determined.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15095955

Source DB:  PubMed          Journal:  Chang Gung Med J        ISSN: 2072-0939


  7 in total

1.  C-28/I2 and T/C-28a2 chondrocytes as well as human primary articular chondrocytes express sex hormone and insulin receptors--Useful cells in study of cartilage metabolism.

Authors:  Horst Claassen; Martin Schicht; Jörg Brandt; Katharina Reuse; Ricarda Schädlich; Mary B Goldring; Saskia Sabrina Guddat; Annett Thate; Friedrich Paulsen
Journal:  Ann Anat       Date:  2010-10-25       Impact factor: 2.698

2.  Pyk2 deficiency potentiates osteoblast differentiation and mineralizing activity in response to estrogen or raloxifene.

Authors:  Sumana Posritong; Jung Min Hong; Pierre P Eleniste; Patrick W McIntyre; Jennifer L Wu; Evan R Himes; Vruti Patel; Melissa A Kacena; Angela Bruzzaniti
Journal:  Mol Cell Endocrinol       Date:  2018-02-08       Impact factor: 4.102

3.  Estrogen receptor-β regulates mechanical signaling in primary osteoblasts.

Authors:  Alesha B Castillo; Jason W Triplett; Fredrick M Pavalko; Charles H Turner
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-03-11       Impact factor: 4.310

4.  Differential regulation of dehydroepiandrosterone and estrogen on bone and uterus in ovariectomized mice.

Authors:  L Wang; Y-D Wang; W-J Wang; D-J Li
Journal:  Osteoporos Int       Date:  2008-08-09       Impact factor: 4.507

5.  Participation of estrogen receptors in the enhancement of osteoblast differentiation by TAK-778.

Authors:  Márcio Mateus Beloti; Larissa Sverzut Bellesini; Paulo Tambasco de Oliveira; Adalberto Luiz Rosa
Journal:  Mol Cell Biochem       Date:  2006-02-14       Impact factor: 3.396

6.  Inhibitory effects of tamoxifen and doxorubicin, alone and in combination, on the proliferation of the MG63 human osteosarcoma cell line.

Authors:  Zheng-Xiao Ouyang; Xian-An Li
Journal:  Oncol Lett       Date:  2013-07-24       Impact factor: 2.967

Review 7.  Molecular mechanisms of estrogen receptor β-induced apoptosis and autophagy in tumors: implication for treating osteosarcoma.

Authors:  Zheng-Ming Yang; Min-Fei Yang; Wei Yu; Hui-Min Tao
Journal:  J Int Med Res       Date:  2019-09-17       Impact factor: 1.671

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.